Drug profile · INN
zolmitriptan
APO-ZOLMITRIPTAN
zolmitriptan (APO-ZOLMITRIPTAN) is a serotonin 1d (5-ht1d) receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: nasal. Current US regulatory status: approved.
Drug details — zolmitriptan
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
zolmitriptan (APO-ZOLMITRIPTAN) is a serotonin 1d (5-ht1d) receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 1d (5-HT1d) receptor agonist
Primary target: 5-hydroxytryptamine receptor 1B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is zolmitriptan?
zolmitriptan (APO-ZOLMITRIPTAN) is a serotonin 1d (5-ht1d) receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for zolmitriptan?
APO-ZOLMITRIPTAN is a marketed brand name for zolmitriptan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zolmitriptan?
zolmitriptan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.